Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 09:58AM ET
1.65
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-1.44 Insider Own20.99% Shs Outstand51.45M Perf Week-4.07%
Market Cap84.88M Forward P/E- EPS next Y-1.53 Insider Trans-0.81% Shs Float40.65M Perf Month-8.84%
Income-68.96M PEG- EPS next Q-0.37 Inst Own85.41% Short Float5.56% Perf Quarter-49.39%
Sales0.00M P/S- EPS this Y3.33% Inst Trans-5.35% Short Ratio4.09 Perf Half Y-73.26%
Book/sh4.39 P/B0.38 EPS next Y-10.09% ROA-26.40% Short Interest2.26M Perf Year-66.05%
Cash/sh3.96 P/C0.42 EPS next 5Y23.10% ROE-29.24% 52W Range1.17 - 9.72 Perf YTD-46.77%
Dividend Est.- P/FCF- EPS past 5Y-28.63% ROI-28.96% 52W High-83.02% Beta1.64
Dividend TTM- Quick Ratio14.78 Sales past 5Y0.00% Gross Margin- 52W Low40.43% ATR (14)0.12
Dividend Ex-Date- Current Ratio14.78 EPS Y/Y TTM10.20% Oper. Margin0.00% RSI (14)43.61 Volatility5.48% 7.57%
Employees63 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price6.00
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q27.64% Payout- Rel Volume0.29 Prev Close1.65
Sales Surprise- EPS Surprise18.92% Sales Q/Q- EarningsFeb 29 AMC Avg Volume551.60K Price1.65
SMA20-4.91% SMA50-4.06% SMA200-58.51% Trades Volume18,889 Change0.00%
Date Action Analyst Rating Change Price Target Change
Dec-27-23Initiated Ladenburg Thalmann Buy $7
Mar-02-22Upgrade Oppenheimer Perform → Outperform $30
Sep-22-21Upgrade Goldman Neutral → Buy $35 → $43
Aug-19-21Initiated Oppenheimer Perform
Aug-02-21Initiated Guggenheim Buy $56
Jul-29-21Initiated H.C. Wainwright Buy $63
Oct-20-20Initiated Goldman Neutral $34
Oct-20-20Initiated Evercore ISI Outperform $60
Oct-20-20Initiated Cowen Outperform
Oct-20-20Initiated BofA Securities Buy $42
Mar-27-24 08:00AM
Mar-18-24 04:01PM
Mar-01-24 10:21AM
Feb-29-24 04:01PM
Feb-26-24 08:00AM
04:01PM Loading…
Jan-18-24 04:01PM
Jan-05-24 04:01PM
Nov-09-23 09:41AM
08:00AM
Oct-16-23 09:35AM
Oct-12-23 12:30PM
Oct-11-23 12:00PM
Oct-06-23 09:55AM
Sep-20-23 04:05PM
Aug-30-23 09:55AM
09:55AM Loading…
Aug-29-23 09:55AM
Aug-09-23 08:00AM
Jun-06-23 04:01PM
May-10-23 08:00AM
Apr-14-23 11:51AM
Mar-01-23 08:00AM
Feb-28-23 04:05PM
Dec-08-22 09:55AM
Nov-22-22 08:00AM
Nov-17-22 06:18PM
Nov-08-22 08:00AM
Nov-05-22 09:39AM
Nov-04-22 08:00AM
Oct-11-22 12:00PM
Sep-23-22 09:19AM
08:00AM Loading…
Aug-09-22 08:00AM
Jul-19-22 09:26AM
Jul-18-22 10:47AM
08:00AM
Jun-08-22 08:00AM
Jun-07-22 12:00PM
May-29-22 08:26AM
May-26-22 05:05PM
May-20-22 03:04PM
May-10-22 07:30AM
Apr-27-22 10:30AM
Mar-01-22 07:15AM
Feb-28-22 08:00AM
Feb-03-22 08:00AM
Jan-12-22 12:20PM
Jan-06-22 08:00AM
Dec-20-21 10:28AM
Nov-22-21 08:00AM
Nov-12-21 07:15AM
Oct-05-21 11:33AM
Sep-27-21 09:26PM
Sep-09-21 08:00AM
Sep-02-21 08:00AM
Aug-13-21 08:00AM
Jul-19-21 06:19PM
Jun-23-21 05:38AM
Jun-09-21 08:00AM
Jun-03-21 08:00AM
May-14-21 08:00AM
May-05-21 08:00AM
Apr-10-21 01:31PM
Apr-06-21 08:00AM
Mar-10-21 04:31PM
Mar-03-21 04:01PM
Feb-16-21 08:00AM
Dec-25-20 03:44AM
Dec-16-20 03:19PM
Nov-24-20 05:00PM
Nov-23-20 08:00AM
Nov-13-20 08:00AM
Oct-13-20 08:00AM
Oct-09-20 03:41PM
Oct-01-20 11:57AM
Sep-29-20 04:05PM
Sep-25-20 02:31PM
12:37PM
06:16AM
Sep-24-20 08:06PM
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLC10% OwnerNov 22 '23Sale2.2387,786195,7630Nov 24 04:38 PM
Mack David HenryPresident and CEOOct 18 '23Option Exercise0.53198,407105,156363,877Nov 13 04:21 PM
Alland LeilaChief Medical OfficerSep 15 '23Sale6.626,29141,64645,909Sep 18 04:22 PM
Jalota DeepikaChief Development OfficerSep 15 '23Sale6.624,10427,16829,946Sep 18 04:26 PM
Mack David HenryPresident and CEOAug 07 '23Option Exercise0.5385,50045,315165,470Aug 08 04:43 PM